Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder
by
Sahai, Arun
, Eldred-Evans, David
in
Botulinum toxin
/ Reviews
2017
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder
by
Sahai, Arun
, Eldred-Evans, David
in
Botulinum toxin
/ Reviews
2017
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder
Journal Article
Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder
2017
Request Book From Autostore
and Choose the Collection Method
Overview
Botulinum toxin A (BoNT-A) has become an important therapeutic tool in the management of refractory overactive bladder (OAB). Over the last decade, there have been growing numbers of patients receiving repeat injections and these outcomes have begun to be reported in large, high-quality cohorts. This article reviews the current evidence for the medium- to long-term use of BoNT-A in adults with idiopathic detrusor overactivity (IDO) receiving repeat injections. We find that medium-term outcomes are encouraging but long-term outcomes are not as extensively reported. There is high-quality evidence that efficacy following the first injection persists across multiple treatment cycles. There are no additional safety concerns from repeat injections up to six treatment cycles. However, there is a need for further data to confirm the efficacy and safety of BoNT-A beyond the follow-up period in the current literature.
Publisher
SAGE Publications,Sage Publications Ltd,SAGE Publishing
Subject
This website uses cookies to ensure you get the best experience on our website.